An investigation for investors in ProNAi Therapeutics Inc (NASDAQ:DNAI) shares over potential securities laws violations by ProNAi Therapeutics was announced and NASDAQ:DNAI stockholders should contact the Shareholders Foundation.

San Diego, CA -- (SBWire) -- 06/14/2016 --An investigation for investors of ProNAi Therapeutics Inc (NASDAQ:DNAI) shares over potential securities laws violations by ProNAi Therapeutics in connection certain financial statements was announced.

Investors who purchased shares of ProNAi Therapeutics Inc (NASDAQ:DNAI), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of ProNAi Therapeutics Inc (NASDAQ:DNAI) concerning whether certain statements by ProNAi Therapeutics regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On June 6, 2016, ProNAi Therapeutics Inc (NASDAQ:DNAI announced interim results from the Wolverine Phase 2 trial of PNT2258 for the treatment of relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL). ProNAi Therapeutics Inc's President and CEO Nick Glover said, "Although [PNT2258] observed modest efficacy …in [the] interim analysis of Wolverine," the Company has "decided to suspend the development of PNT2258" because the results were not "robust enough to justify continued development of the drug in DLBCL."

Shares of ProNAi Therapeutics Inc (NASDAQ:DNAI) declined from $6.70 per share on June 2, 2016, to $1.98 per share on June 10, 2016.

Those who purchased shares of ProNAi Therapeutics Inc have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com